**Table S1** Kinase inhibitory profiling studies of CB538 on Axl and other tyrosine kinases

| Kinase inhibition(%) at 0.5 μM CB538 | |
|---|---|
| Kinase | Kinase inhibition(%) |
| Abl | 0 |
| B-Raf | 0 |
| cSRC | 5 |
| EGFR | 0 |
| Flt | 0 |
| Fms | 4 |
| FGFR | 0 |
| cKit | 0 |
| KDR | 7 |
| PDGFR | 0 |
| RET | 0 |
| Syk | 12 |
| DDR1 | 48 |
| AxL | 68 |
| Ron | 76 |
| Mer | 100 |

The in vitro ability of CB538 to inhibit kinases in biochemical formats was conducted by Eurofins Pharma Discovery Service (Dundee, UK), and the inhibition potency of CB538 was incubated with a fixed concentration of recombinant human enzyme at the $K_m$ value of ATP.

**Table S2** Kinase inhibitory effect of CB538 on MET kinases

| Kinase, $IC_{50}$ (nM) | CB538 | Glesatinib | Type I inhibitor | |
|---|---|---|---|---|
| | | | Capmatinib | Crizotinib |
| MET | 0.5 | 10.2 | 55.5 | 261.6 |
| MET exon14del | 17.1 | 7.4 | 31.9 | 34.1 |
| MET D1228N | 2.1 | 7.3 | 6,901 | 107.5 |
| MET D1228Y | 0.2 | N/A | N/A | N/A |
| MET Y1230H | 0.7 | 1.5 | >10,000 | 145.9 |

The in vitro kinase assay was measured by 10-point concentration-response using the ADP-Glo™ luminescent kinase and the c-Met enzyme inhibition potency of MET-TKIs was determined using recombinant human c-Met protein. $IC_{50}$ was evaluated at 10 μmol/L ATP. N/A, not applicable.


https://dx.doi.org/10.21037/tcr-24-1614